ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror
Abstract During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discusses, from a pharmacological point of view, the points of weakness in the mentioned correspondence and it also lists some important contradictory review articles as well as clinical results that refuted its claims. The author chose to argue against each claim represented in the mentioned correspondence to confirm that ACEIs, ARBs and NSAIDs including ibuprofen should not be considered hazardous to be administered for COVID-19 patients and to warn against any future adoption of such unproved claims..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 28(2020), 6 vom: 12. Sept., Seite 1477-1480 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kelleni, Mina T. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s10787-020-00755-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR041451481 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR041451481 | ||
| 003 | DE-627 | ||
| 005 | 20230519084419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201102s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-020-00755-x |2 doi | |
| 035 | |a (DE-627)SPR041451481 | ||
| 035 | |a (SPR)s10787-020-00755-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Kelleni, Mina T. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discusses, from a pharmacological point of view, the points of weakness in the mentioned correspondence and it also lists some important contradictory review articles as well as clinical results that refuted its claims. The author chose to argue against each claim represented in the mentioned correspondence to confirm that ACEIs, ARBs and NSAIDs including ibuprofen should not be considered hazardous to be administered for COVID-19 patients and to warn against any future adoption of such unproved claims. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Aceis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Arbs |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ibuprofen |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d Cham : Springer International Publishing AG, 1991 |g 28(2020), 6 vom: 12. Sept., Seite 1477-1480 |w (DE-627)SPR013448595 |w (DE-600)2047989-X |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:6 |g day:12 |g month:09 |g pages:1477-1480 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10787-020-00755-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 6 |b 12 |c 09 |h 1477-1480 | ||